NasdaqGM - Delayed Quote USD

Trevi Therapeutics, Inc. (TRVI)

18.09 -0.34 (-1.84%)
At close: July 29 at 4:00:01 PM EDT
17.91 -0.18 (-1.00%)
Pre-Market: 7:16:12 AM EDT
Trade TRVI on Coinbase
Chart Range Bar
Loading chart for TRVI
  • Previous Close 18.43
  • Open 18.47
  • Bid 13.15 x 200
  • Ask 22.87 x 200
  • Day's Range 17.69 - 18.53
  • 52 Week Range 6.55 - 20.22
  • Volume 1,428,364
  • Avg. Volume 2,091,262
  • Market Cap (intraday) 2.568B
  • Beta (5Y Monthly) 1.00
  • PE Ratio (TTM) --
  • EPS (TTM) -0.32
  • Earnings Date Aug 6, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 26.18

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.

www.trevitherapeutics.com

34

Full Time Employees

December 31

Fiscal Year Ends

Performance Overview

Trailing total returns as of 7/29/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

TRVI
44.49%
S&P 500 (^GSPC)
6.88%

1-Year Return

TRVI
139.60%
S&P 500 (^GSPC)
14.84%

3-Year Return

TRVI
689.96%
S&P 500 (^GSPC)
59.66%

5-Year Return

TRVI
847.12%
S&P 500 (^GSPC)
65.56%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized
 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue --
Earnings -13.19M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-10M
-5M
0
 

Analyst Insights

View More

Analyst Price Targets

20.00
26.18 Average
18.09 Current
36.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Latest Rating

Date 7/21/2026
Analyst BMO Capital
Rating Action Initiated
Rating Outperform
Price Action Announces
Price Target 36
 

Statistics

View More

Valuation Measures

Annual
As of 7/28/2026
  • Market Cap

    2.62B

  • Enterprise Value

    2.45B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    15.20

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -23.01%

  • Return on Equity (ttm)

    -33.59%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -45.61M

  • Diluted EPS (ttm)

    -0.32

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    171.78M

  • Total Debt/Equity (mrq)

    0.40%

  • Levered Free Cash Flow (ttm)

    -28.53M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

18.09 Current
 

Dividend Score

0 Low
Sector Avg.
100 High
 

Hiring Score

0 Low
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
Sector Avg.
100 High
 

People Also Watch